Blackhawk Plastic Surgery and other practices report a significant uptick in body-contouring procedures, directly attributable to the GLP-1 agonist boom. Patients losing 50+ pounds on semaglutide (Ozempic, Wegovy) or tirzepatide (Zepbound, Mounjaro) are seeking skin-tightening, cellulite reduction, and body-sculpting treatments to address loose skin and contour irregularities—a natural follow-on to weight loss.
Market
GLP-1 Weight-Loss Boom Fuels Body-Contouring Volume — Practices Report Surge in Post-Weight-Loss Procedures
Ozempic/Wegovy patients driving demand for skin-tightening and body-sculpting treatments.
GLP-1 weight-loss patients are driving a surge in body-contouring procedures.
For medspa and aesthetic-surgery practices, this represents a new patient acquisition funnel and an opportunity to expand service lines. RF microneedling, monopolar RF, and body-sculpting devices (radiofrequency, ultrasound, or cryolipolysis) are seeing increased utilization. However, the market is time-sensitive: GLP-1 adoption peaked in 2023–2024, and saturation is rising. Practices should evaluate their device mix and staffing capacity now. The body-contouring surge also attracts new competition—general surgeons and dermatologists are adding these services—so differentiation through clinical outcomes, patient education, and pricing strategy is critical.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.